Vardy J, Engelhardt K, Cox K, Jacquet J, McDade A, Boyer M, Beale P, Stockler M, Loneragan R, Dennien B, Waugh R, Clarke S J
Royal Prince Alfred Hospital, Missenden Rd, Camperdown, 2050 NSW, Australia.
Br J Cancer. 2004 Sep 13;91(6):1045-9. doi: 10.1038/sj.bjc.6602082.
Central venous access port devices (CVAPD) are necessary for delivery of prolonged infusional chemotherapy or in patients with poor peripheral venous access. Previous studies of Hickman catheters report complication rates in about 45% of patients. Our aim was to assess the early and late complication rate, and duration that the CVAPD remained functional, following insertion by interventional radiologists in patients with solid tumours. A prospective study was undertaken in 110 consecutive patients who had insertion of 111 subclavian CVAPD. The median age of patients was 57 years (range 17-83), 64 were females; 68 patients (61%) had gastrointestinal tumours and 25 (23%) had breast cancer. CVAPD were successfully implanted in all but one patient. There were four (4%) immediate major complications: thrombosis 2 and pneumothorax 2. Nine patients (8%) had bruising or pain. Four devices (4%) became infected. In total, 100 CVAPD (90%) were either removed as planned at the end of treatment (n=23) after a median 203 days, or remained in situ for a median of 237 days (7-1133). Premature removal occurred in eight patients due to infection (n=4), thrombosis (n=3) or faulty device (n=1). Four patients were lost to follow-up. Radiological insertion of CVAPD is safe and convenient with low rates of complications.
中心静脉通路端口装置(CVAPD)对于长期输注化疗药物或外周静脉通路不佳的患者来说是必要的。先前关于希克曼导管的研究报告称,约45%的患者会出现并发症。我们的目的是评估实体瘤患者经介入放射科医生插入CVAPD后的早期和晚期并发症发生率,以及CVAPD保持功能的持续时间。对110例连续插入111个锁骨下CVAPD的患者进行了一项前瞻性研究。患者的中位年龄为57岁(范围17 - 83岁),女性64例;68例患者(61%)患有胃肠道肿瘤,25例(23%)患有乳腺癌。除1例患者外,所有患者的CVAPD均成功植入。有4例(4%)立即出现严重并发症:血栓形成2例,气胸2例。9例患者(8%)出现瘀伤或疼痛。4个装置(4%)发生感染。总共100个CVAPD(90%)在治疗结束时(n = 23)按计划拔除,中位时间为203天,或中位原位保留237天(7 - 1133天)。8例患者因感染(n = 4)、血栓形成(n = 3)或装置故障(n = 1)而提前拔除。4例患者失访。经放射学方法插入CVAPD安全方便,并发症发生率低。